- 25
- Kilograms/Kilograms
- 25.00-
- Freezer
- C17H25N3O2
- 303.4 g/mol
- 531.3±50.0 °C at 760 mmHg
- Medicine Grade
- 98%
- Pharmaceutical Industry
- Liquid
Vildagliptin | |
Clinical data | |
Galvus/Gliptus | |
Synonyms | (2S)-1-{2-[(3-hydroxy-1-adamantyl)amino]acetyl}pyrrolidine-2-carbonitrile |
Oral | |
Legal status | |
· UK: POM (Prescription only) | |
Pharmacokinetic data | |
85% | |
9.3% | |
Mainly hydrolysis to inactive metabolite; CYP450 not appreciably involved | |
2 to 3 hours | |
Identifiers | |
· 274901-16-5 | |
PubChem CID | · 6918537 |
· 6310 | |
· DB04876 | |
· 5293734 | |
· I6B4B2U96P | |
· D07080 | |
· CHEMBL142703 | |
Chemical and physical data | |
C17H25N3O2 | |
303.399 g/mol | |
3D model (JSmol) | |
Freely Soluble in water mg/mL (20 °C) | |
Vildagliptin (previously LAF237, trade names Galvus, Zomelis,) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1[2][3] and GIP[3] by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.[2]
Our packaging materials can retain the products' quality and newness even under extreme shipping and handling conditions. Our packaging provides optimum physical protection. We keep the finished assortment of products in highly developed and spacious space. This helps us in keeping products secure and sorted.
- Cash Advance (CA), Cash in Advance (CID)
- 1000 Per Day
- 7 Days
- Middle East, Asia, Africa, Western Europe, Eastern Europe, South America, North America, Central America, Australia
- GMP,DMF
311, Atlantis Heights, Sarabhai Main Road,Vadiwadi Vadodara Gujarat India +918037400111
Phone :+918037400111